ChAdOx1-vectored COVID-19 Variant Vaccine AZD2816

**Semantic type:** Immunologic Factor|Pharmacologic Substance

**Definition:** A vaccine composed of a replication-deficient chimpanzee adenovirus, ChAdOx1, encoding the spike (S) glycoprotein of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) beta (B.1.351, South African) variant, with potential immunomodulating and anti-viral activities. Upon administration, ChAdOx1-vectored COVID-19 variant vaccine AZD2816 expresses the SARS-CoV-2 beta variant S protein, which contains ten changes across the S protein. This induces a humoral and cell-mediated immune response against SARS-CoV-2, and may prevent SARS-CoV-2 infection and inhibit viral replication. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus. AZD2816 may induce neutralizing antibodies against SARS-CoV-2 variants including beta, gamma (P.1) and delta (B.1.617.2).

**Synonyms:** - AZD 2816 - AZD-2816 - AZD2816 - B.1.351 Vaccine AZD2816 - SARS-CoV-2 Vaccine AZD2816